Novozymes A/S B
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as protein solutions and … Read more
Market Cap & Net Worth: Novozymes A/S B (NVZMF)
Novozymes A/S B (PINK:NVZMF) has a market capitalization of $23.86 Billion ($23.86 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #969 globally and #755 in its home market, demonstrating a 2.95% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Novozymes A/S B's stock price $57.91 by its total outstanding shares 411941947 (411.94 Million).
Novozymes A/S B Market Cap History: 2015 to 2025
Novozymes A/S B's market capitalization history from 2015 to 2025. Data shows growth from $17.16 Billion to $23.86 Billion (5.08% CAGR).
Novozymes A/S B Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Novozymes A/S B's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.84x
Novozymes A/S B's market cap is 0.84 times its annual revenue
0.59x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
10.57x
Novozymes A/S B's market cap is 10.57 times its annual earnings
710.94x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $17.16 Billion | $14.00 Billion | $2.82 Billion | 1.23x | 6.08x |
| 2016 | $12.45 Billion | $14.14 Billion | $3.05 Billion | 0.88x | 4.08x |
| 2017 | $21.19 Billion | $14.53 Billion | $3.12 Billion | 1.46x | 6.79x |
| 2018 | $16.77 Billion | $14.39 Billion | $3.23 Billion | 1.17x | 5.20x |
| 2019 | $18.47 Billion | $14.37 Billion | $3.15 Billion | 1.28x | 5.85x |
| 2020 | $22.02 Billion | $14.01 Billion | $2.83 Billion | 1.57x | 7.79x |
| 2021 | $32.10 Billion | $14.95 Billion | $3.15 Billion | 2.15x | 10.20x |
| 2022 | $19.90 Billion | $17.55 Billion | $3.68 Billion | 1.13x | 5.41x |
| 2023 | $22.44 Billion | $17.91 Billion | $3.03 Billion | 1.25x | 7.42x |
| 2024 | $24.10 Billion | $28.59 Billion | $2.28 Billion | 0.84x | 10.57x |
Competitor Companies of NVZMF by Market Capitalization
Companies near Novozymes A/S B in the global market cap rankings as of March 18, 2026.
Key companies related to Novozymes A/S B by market ranking:
- Linde plc Ordinary Shares (NASDAQ:LIN): Ranked #71 globally with a market cap of $210.18 Billion USD.
- L'Air Liquide S.A (PINK:AIQUF): Ranked #182 globally with a market cap of $107.70 Billion USD.
- Air Liquide SA (PA:AI): Ranked #200 globally with a market cap of $99.38 Billion USD ( €96.82 Billion EUR).
- Ecolab Inc (NYSE:ECL): Ranked #266 globally with a market cap of $77.81 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #71 | Linde plc Ordinary Shares | NASDAQ:LIN | $210.18 Billion | $494.05 |
| #182 | L'Air Liquide S.A | PINK:AIQUF | $107.70 Billion | $187.03 |
| #200 | Air Liquide SA | PA:AI | $99.38 Billion | €172.22 |
| #266 | Ecolab Inc | NYSE:ECL | $77.81 Billion | $272.59 |
Novozymes A/S B Historical Marketcap From 2015 to 2025
Between 2015 and today, Novozymes A/S B's market cap moved from $17.16 Billion to $ 23.86 Billion, with a yearly change of 5.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $23.86 Billion | -1.01% |
| 2024 | $24.10 Billion | +7.39% |
| 2023 | $22.44 Billion | +12.75% |
| 2022 | $19.90 Billion | -37.99% |
| 2021 | $32.10 Billion | +45.78% |
| 2020 | $22.02 Billion | +19.23% |
| 2019 | $18.47 Billion | +10.13% |
| 2018 | $16.77 Billion | -20.88% |
| 2017 | $21.19 Billion | +70.19% |
| 2016 | $12.45 Billion | -27.43% |
| 2015 | $17.16 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Novozymes A/S B was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $23.86 Billion USD |
| MoneyControl | $23.86 Billion USD |
| MarketWatch | $23.86 Billion USD |
| marketcap.company | $23.86 Billion USD |
| Reuters | $23.86 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.